MX381319B - Combinaciones antihelmínticas y métodos de uso de ellas. - Google Patents

Combinaciones antihelmínticas y métodos de uso de ellas.

Info

Publication number
MX381319B
MX381319B MX2017012510A MX2017012510A MX381319B MX 381319 B MX381319 B MX 381319B MX 2017012510 A MX2017012510 A MX 2017012510A MX 2017012510 A MX2017012510 A MX 2017012510A MX 381319 B MX381319 B MX 381319B
Authority
MX
Mexico
Prior art keywords
methods
prophylaxis
treatment
macrocyclic lactone
anthelmintic
Prior art date
Application number
MX2017012510A
Other languages
English (en)
Spanish (es)
Other versions
MX2017012510A (es
Inventor
Brenda Bondesen
Lance Hammerland
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of MX2017012510A publication Critical patent/MX2017012510A/es
Publication of MX381319B publication Critical patent/MX381319B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017012510A 2015-04-02 2016-04-01 Combinaciones antihelmínticas y métodos de uso de ellas. MX381319B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562142304P 2015-04-02 2015-04-02
PCT/US2016/025714 WO2016161369A1 (en) 2015-04-02 2016-04-01 Anthelmintic combinations and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2017012510A MX2017012510A (es) 2018-01-30
MX381319B true MX381319B (es) 2025-03-12

Family

ID=57006415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012510A MX381319B (es) 2015-04-02 2016-04-01 Combinaciones antihelmínticas y métodos de uso de ellas.

Country Status (18)

Country Link
US (1) US10993988B2 (cg-RX-API-DMAC10.html)
EP (1) EP3277303B1 (cg-RX-API-DMAC10.html)
JP (1) JP6899330B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170132330A (cg-RX-API-DMAC10.html)
CN (1) CN107567334A (cg-RX-API-DMAC10.html)
AU (1) AU2016244022A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017020975A2 (cg-RX-API-DMAC10.html)
CA (1) CA2981489A1 (cg-RX-API-DMAC10.html)
CL (1) CL2017002474A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017011284A2 (cg-RX-API-DMAC10.html)
ES (1) ES2851345T3 (cg-RX-API-DMAC10.html)
IL (1) IL254783B (cg-RX-API-DMAC10.html)
MX (1) MX381319B (cg-RX-API-DMAC10.html)
MY (1) MY187835A (cg-RX-API-DMAC10.html)
PH (1) PH12017501806A1 (cg-RX-API-DMAC10.html)
RU (1) RU2717545C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201708008TA (cg-RX-API-DMAC10.html)
WO (1) WO2016161369A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019009977A2 (pt) * 2016-11-16 2019-08-27 Boehringer Ingelheim Animal Health Usa Inc compostos depsipeptídicos anti-helmínticos
EP3579696B1 (en) * 2017-02-08 2023-06-28 Boehringer Ingelheim Animal Health USA Inc. In vivo model for parasitic worm infection and methods for evaluating antiparasitic compounds, including compounds active against canine heartworm
BR112020010291A2 (pt) 2017-11-23 2020-11-17 Ceva Sante Animale composição contendo moxidectina para tratamento de infestações de parasitas
RU2747149C9 (ru) * 2017-11-29 2021-06-29 ЗОЕТИС СЕРВИСИЗ ЭлЭлСи Анти-эндопаразитарные депсипептиды
AR116524A1 (es) * 2018-10-04 2021-05-19 Elanco Tiergesundheit Ag Potenciación de tratamiento de helmintos
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
GB202100635D0 (en) * 2021-01-18 2021-03-03 Liverpool School Tropical Medicine Compounds and methods for treating or preventing dirofilaria infection in a mammal
WO2023073641A1 (en) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134973A (en) 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
GB9300883D0 (en) 1993-01-18 1993-03-10 Pfizer Ltd Antiparasitic agents
DE19520275A1 (de) * 1995-06-02 1996-12-05 Bayer Ag Endoparasitizide Mittel
US20030129680A1 (en) 2001-10-31 2003-07-10 O'connor Thomas Patrick Multi-analyte assay device
US20070042354A1 (en) 2005-08-19 2007-02-22 Engelhard Eric K Detecting pathogens in companion animals
WO2008102232A1 (en) * 2007-02-21 2008-08-28 Pfizer Limited Benzofuran antiparasitic agents
JP4734656B2 (ja) * 2007-03-30 2011-07-27 国立大学法人群馬大学 Pf1022類の製造法
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US8809268B2 (en) 2008-10-29 2014-08-19 The Regents Of The University Of California Combination therapy to combat helminth resistance
BE1019407A5 (nl) 2009-11-06 2012-07-03 Momentum Animal Cure Bvba Middel voor het uitdrijven van parasieten bij mensen, dieren en vogels.
WO2011095581A1 (en) 2010-02-05 2011-08-11 Intervet International B.V. S piroindoline compounds for use as anthelminthi cs
WO2011115840A2 (en) 2010-03-14 2011-09-22 Ibis Biosciences, Inc. Parasite detection via endosymbiont detection
RU2452180C2 (ru) * 2010-08-31 2012-06-10 Общество с ограниченной ответственностью "Научно-внедренческое предприятие "Астрафарм" Комплексная антипаразитарная композиция
AU2010249226C1 (en) 2010-12-08 2017-04-13 Zoetis Services Llc Anthelmintic formulation
AU2010101389C4 (en) 2010-12-08 2017-03-02 Jurox Pty Ltd Anthelmintic formulation
WO2013017678A1 (en) 2011-08-04 2013-02-07 Intervet International B.V. Novel spiroindoline compounds

Also Published As

Publication number Publication date
MX2017012510A (es) 2018-01-30
MY187835A (en) 2021-10-26
EP3277303B1 (en) 2020-12-02
IL254783A0 (en) 2017-12-31
CN107567334A (zh) 2018-01-09
SG11201708008TA (en) 2017-10-30
AU2016244022A1 (en) 2017-10-26
CA2981489A1 (en) 2016-10-06
WO2016161369A1 (en) 2016-10-06
EP3277303A1 (en) 2018-02-07
US10993988B2 (en) 2021-05-04
US20170020955A1 (en) 2017-01-26
RU2717545C2 (ru) 2020-03-24
BR112017020975A2 (pt) 2018-07-10
RU2017138118A (ru) 2019-05-06
CO2017011284A2 (es) 2018-01-31
JP6899330B2 (ja) 2021-07-07
PH12017501806A1 (en) 2018-04-11
ES2851345T3 (es) 2021-09-06
CL2017002474A1 (es) 2018-03-23
RU2017138118A3 (cg-RX-API-DMAC10.html) 2019-07-24
JP2018510195A (ja) 2018-04-12
IL254783B (en) 2020-11-30
KR20170132330A (ko) 2017-12-01

Similar Documents

Publication Publication Date Title
PH12017501806A1 (en) Anthelmintic combinations and methods of use thereof
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
MX2016003216A (es) Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
MX383929B (es) Derivados y métodos de tratamiento de las infecciones por hepatitis b.
MX2015010190A (es) Metodos de tratamiento topico para infecciones microbianas.
BR112017006113A2 (pt) combinações sinérgicas de auristatina
MX2021000189A (es) Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias.
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
MX389999B (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
EA201500942A1 (ru) ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
MX2015008486A (es) Composiciones y metodos para tratar infecciones bacterianas.
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
UY36045A (es) Formulaciones antihelmínticas veterinarias estables
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
CL2015002976A1 (es) Composición de lactonas macrocíclicas, levamisol, un amino azúcar y un agente antiparasitario adicional.